9U9 Stock Overview
A biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Unity Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.09 |
| 52 Week High | US$1.89 |
| 52 Week Low | US$1.05 |
| Beta | 0.83 |
| 11 Month Change | -14.22% |
| 3 Month Change | -19.56% |
| 1 Year Change | -40.17% |
| 33 Year Change | -94.66% |
| 5 Year Change | n/a |
| Change since IPO | -99.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9U9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.7% | 0.8% | -1.3% |
| 1Y | -40.2% | -17.5% | 7.4% |
Return vs Industry: 9U9 underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 9U9 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 9U9 volatility | |
|---|---|
| 9U9 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9U9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9U9's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 19 | Anirvan Ghosh | unitybiotechnology.com |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
Unity Biotechnology, Inc. Fundamentals Summary
| 9U9 fundamental statistics | |
|---|---|
| Market cap | €18.80m |
| Earnings (TTM) | -€20.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs 9U9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9U9 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$18.39m |
| Gross Profit | -US$18.39m |
| Other Expenses | US$3.50m |
| Earnings | -US$21.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 9U9 perform over the long term?
See historical performance and comparison